CompletedNCT02832037
BI 425809 for Cognition and Daily Function in Schizophrenia
About this title
Read the official source — NCT02832037Medication studyAges 18–50Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- Garden Grove and 80 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: July 25, 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 509
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada, United Kingdom, ...
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT02832037
- Official title
Show the full official title
A Phase II Randomised, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 425809 Once Daily Over 12 Week Treatment Period in Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Garden Grove, United States · Lemon Grove, United States · Orange, United States
68 more locations
- Panorama City, United States
- Pico Rivera, United States
- San Diego, United States
- Miami, United States
- Atlanta, United States
- Chicago, United States
- Lake Charles, United States
- Ann Arbor, United States
- St Louis, United States
- Buffalo, United States
- Cedarhurst, United States
- Rochester, United States
- Raleigh, United States
- Dayton, United States
- DeSoto, United States
- Salt Lake City, United States
- Bellevue, United States
- Innsbruck, Austria
- Vienna, Austria
- Penticton, Canada
- Vancouver, Canada
- Chatham, Canada
- Toronto, Canada
- Montreal, Canada
- Bad Homburg, Germany
- Berlin, Germany
- Leipzig, Germany
- Mannheim, Germany
- Westerstede, Germany
- Concesio (BS), Italy
- Milan, Italy
- Orbassano (TO), Italy
- Aichi, Toyoake, Japan
- Chiba, Chiba, Japan
- Chiba, Ichikawa, Japan
- Fukuoka, Kitakyushu, Japan
- Hokkaido, Sapporo, Japan
- Hyogo, Kobe, Japan
- Kagawa, Kita-gun, Japan
- Kanagawa, Kawasaki, Japan
- Nara, Kashihara, Japan
- Osaka, Moriguchi, Japan
- Tokushima, Anan, Japan
- Tokyo, Kodaira, Japan
- Tokyo, Setagaya, Japan
- Tokyo, Shinjuku-ku, Japan
- Bialystok, Poland
- Bydgoszcz, Poland
- Leszno, Poland
- Szczecin, Poland
- Torun, Poland
- Warsaw, Poland
- Gwangju, South Korea
- Incheon, South Korea
- Seongnam, South Korea
- Seoul, South Korea
- Barcelona, Spain
- Madrid, Spain
- Majadahonda (Madrid), Spain
- Salamanca, Spain
- Santander, Spain
- Tainan, Taiwan
- Taipei, Taiwan
- Dudley, United Kingdom
- Edinburgh, United Kingdom
- Glasgow, United Kingdom
- London, United Kingdom
- Truro, United Kingdom
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Boehringer Ingelheim.
Did this study involve medication?
Yes. The study involved medication, including BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3, BI 425809 dose 4 and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
